ATE356640T1 - Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendung - Google Patents
Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendungInfo
- Publication number
- ATE356640T1 ATE356640T1 AT01991925T AT01991925T ATE356640T1 AT E356640 T1 ATE356640 T1 AT E356640T1 AT 01991925 T AT01991925 T AT 01991925T AT 01991925 T AT01991925 T AT 01991925T AT E356640 T1 ATE356640 T1 AT E356640T1
- Authority
- AT
- Austria
- Prior art keywords
- arterial
- smooth muscle
- cells
- muscle cells
- venous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25200900P | 2000-11-20 | 2000-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE356640T1 true ATE356640T1 (de) | 2007-04-15 |
Family
ID=22954256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01991925T ATE356640T1 (de) | 2000-11-20 | 2001-11-20 | Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendung |
Country Status (9)
Country | Link |
---|---|
US (1) | US7163808B2 (de) |
EP (1) | EP1337276B1 (de) |
JP (1) | JP2004529614A (de) |
AT (1) | ATE356640T1 (de) |
AU (1) | AU2002232405A1 (de) |
CA (1) | CA2429460A1 (de) |
DE (1) | DE60127291T2 (de) |
IL (1) | IL156009A0 (de) |
WO (1) | WO2002040540A2 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
US8147824B2 (en) | 1999-08-05 | 2012-04-03 | Athersys, Inc. | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
WO2002058538A2 (en) * | 2001-01-26 | 2002-08-01 | Regeneron Pharmaceuticals, Inc. | Methods of imaging and targeting vasculature |
WO2003078597A2 (en) * | 2002-03-15 | 2003-09-25 | Duke University | Tissue engineering |
US7862816B2 (en) * | 2003-03-12 | 2011-01-04 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US7584092B2 (en) * | 2004-11-15 | 2009-09-01 | Microsoft Corporation | Unsupervised learning of paraphrase/translation alternations and selective application thereof |
CN102746401A (zh) | 2004-03-12 | 2012-10-24 | 瓦斯基因治疗公司 | 结合ephb4、抑制血管发生和肿瘤生长的抗体 |
CN101072797B (zh) * | 2004-03-12 | 2012-05-09 | 瓦斯基因治疗公司 | 结合ephb4、抑制血管发生和肿瘤生长的抗体 |
JP2007320850A (ja) * | 2004-08-24 | 2007-12-13 | Kyowa Hakko Kogyo Co Ltd | 抗エフリンb2抗体 |
AU2005286662B2 (en) * | 2004-09-23 | 2011-10-06 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
AU2006210837B2 (en) * | 2005-01-31 | 2012-07-12 | Genentech, Inc. | Anti-EphB2 antibodies and methods using same |
CA2623387A1 (en) * | 2005-09-23 | 2007-04-05 | Vasgene Therapeutics, Inc. | Use of ephrinb2 directed agents for the treatment or prevention of viral infections |
JPWO2007043629A1 (ja) * | 2005-10-05 | 2009-04-16 | アキュメンバイオファーマ株式会社 | エフリンb2を用いる血管新生の抑制方法 |
US11000546B2 (en) | 2005-11-09 | 2021-05-11 | Athersys, Inc. | Immunomodulatory properties of MAPCs and uses thereof |
JP5368110B2 (ja) | 2006-01-20 | 2013-12-18 | ジェネンテック, インコーポレイテッド | 抗エフリンb2抗体とその使用方法 |
US20110009323A1 (en) * | 2007-06-15 | 2011-01-13 | Vasgene Therapeutics, Inc. | Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth |
BRPI0815399A2 (pt) * | 2007-08-13 | 2019-09-24 | Vasgene Therapeutics Inc | tratamento de câncer usando anticorpos humanizados que se ligam ephb4 |
US20090136465A1 (en) | 2007-09-28 | 2009-05-28 | Intrexon Corporation | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof |
WO2011153464A2 (en) * | 2010-06-03 | 2011-12-08 | New York University | In situ oriented immobilization of proteins on a support |
EP3412769B1 (de) * | 2016-02-03 | 2021-09-01 | BGI Shenzhen | Verfahren zur trennung einer zielzelle aus einer blutprobe und verwendung davon |
US20220133672A1 (en) * | 2018-12-18 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Notch inhibitors for the treatment of vascular malformations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2152753B1 (es) | 1993-03-29 | 2001-09-01 | Ct Investig Energeticas Ciemat | Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo |
WO1996026958A2 (en) | 1995-02-27 | 1996-09-06 | President And Fellows Of Harvard College | Eph RECEPTOR LIGAND ELF-2 |
US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
US6440954B1 (en) * | 1997-04-18 | 2002-08-27 | President And Fellows Of Harvard College | Inhibition of vascular smooth muscle cell proliferation |
US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
EP0999278B1 (de) * | 1998-10-02 | 2004-03-31 | Universite Paris Vii | Vaskulär-spezifische regulatorische Elemente aus der 5' flankierenden Region des Desmingens |
EP1135153B1 (de) | 1998-11-20 | 2005-04-27 | Genentech, Inc. | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
-
2001
- 2001-11-20 EP EP01991925A patent/EP1337276B1/de not_active Expired - Lifetime
- 2001-11-20 AU AU2002232405A patent/AU2002232405A1/en not_active Abandoned
- 2001-11-20 US US09/988,496 patent/US7163808B2/en not_active Expired - Lifetime
- 2001-11-20 IL IL15600901A patent/IL156009A0/xx unknown
- 2001-11-20 JP JP2002543548A patent/JP2004529614A/ja not_active Withdrawn
- 2001-11-20 AT AT01991925T patent/ATE356640T1/de not_active IP Right Cessation
- 2001-11-20 WO PCT/US2001/042961 patent/WO2002040540A2/en active IP Right Grant
- 2001-11-20 CA CA002429460A patent/CA2429460A1/en not_active Abandoned
- 2001-11-20 DE DE60127291T patent/DE60127291T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2004529614A (ja) | 2004-09-30 |
DE60127291T2 (de) | 2007-12-20 |
DE60127291D1 (de) | 2007-04-26 |
EP1337276B1 (de) | 2007-03-14 |
US7163808B2 (en) | 2007-01-16 |
EP1337276A2 (de) | 2003-08-27 |
AU2002232405A1 (en) | 2002-05-27 |
WO2002040540A2 (en) | 2002-05-23 |
WO2002040540A3 (en) | 2003-01-16 |
US20020136726A1 (en) | 2002-09-26 |
IL156009A0 (en) | 2003-12-23 |
CA2429460A1 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE356640T1 (de) | Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendung | |
WO1999052541A3 (en) | Artery- and vein-specific proteins and uses therefor | |
Bochenek et al. | Ephrin-B2 regulates endothelial cell morphology and motility independently of Eph-receptor binding | |
Konstantoulaki et al. | Protein kinase C modifications of VE-cadherin, p120, and β-catenin contribute to endothelial barrier dysregulation induced by thrombin | |
Ruggeri et al. | Activation-independent platelet adhesion and aggregation under elevated shear stress | |
Cimmino et al. | The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor? | |
Brass et al. | Transport physics and biorheology in the setting of hemostasis and thrombosis | |
Hasson et al. | Increased compliance near vascular anastomoses | |
Shi et al. | Interstitial flow promotes vascular fibroblast, myofibroblast, and smooth muscle cell motility in 3-D collagen I via upregulation of MMP-1 | |
Kanno | The role of fibrinolytic regulators in vascular dysfunction of systemic sclerosis | |
Sun et al. | The roles of ADAMTS in angiogenesis and cancer | |
Fu et al. | Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis | |
Kato et al. | Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx | |
Lüscher | Endothelial dysfunction: the role and impact of the renin-angiotensin system | |
Scehnet et al. | The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade | |
Bloom et al. | Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. | |
AR030236A1 (es) | Moléculas similares a il-17 y usos de las mismas | |
HUP0105337A2 (hu) | Az immunválaszban szerepet játszó új polipeptidek | |
Mukherjee et al. | Trypanosoma cruzi infection activates extracellular signal-regulated kinase in cultured endothelial and smooth muscle cells | |
Ruttmann | Editorial II: Haemodilution enhances coagulation | |
AR030554A1 (es) | Moleculas similares a receptores il-17 y usos de las mismas | |
Appert-Collin et al. | Role of LRP-1 in cancer cell migration in 3-dimensional collagen matrix | |
Moffatt et al. | Endothelium‐dependent and‐independent responses to protease‐activated receptor‐2 (PAR‐2) activation in mouse isolated renal arteries | |
Oddie et al. | Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers. | |
Dhahri et al. | Fibrinolytic crosstalk with endothelial cells expands murine mesenchymal stromal cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |